Cancer drug fund extension relieves firms
This article was originally published in Scrip
Executive Summary
England's Cancer Drugs Fund is set to live on for another two years beyond the date it was supposed to be superseded by a new pricing set up. Manufacturers of oncology drugs will likely welcome another two years of greater stability while uncertainty over the UK's pricing landscape continues.